QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Aclaris Therapeutics Stock Price, News & Analysis (NASDAQ:ACRS)

$0.87
0.00 (0.00%)
(As of 11/30/2023 ET)
Compare
Today's Range
$0.84
$0.91
50-Day Range
$0.64
$6.85
52-Week Range
$0.59
$18.54
Volume
2.61 million shs
Average Volume
1.65 million shs
Market Capitalization
$61.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.17

Aclaris Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,548.5% Upside
$23.17 Price Target
Short Interest
Bearish
10.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Aclaris Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$30,480 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.65) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

324th out of 949 stocks

Pharmaceutical Preparations Industry

134th out of 436 stocks


ACRS stock logo

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Stock Price History

ACRS Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Latest Analyst Ratings for Aclaris Therapeutics
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Aclaris Therapeutics Inc ACRS
Expert Ratings for Aclaris Therapeutics
Jefferies Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$23.17
High Stock Price Target
$38.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+2,548.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-86,910,000.00
Net Margins
-534.83%
Pretax Margin
-534.83%

Debt

Sales & Book Value

Annual Sales
$29.75 million
Book Value
$2.21 per share

Miscellaneous

Free Float
66,901,000
Market Cap
$61.92 million
Optionable
Optionable
Beta
0.65

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Neal S. Walker D.O. (Age 53)
    Co-Founder & Chairman
    Comp: $955.69k
  • Dr. Douglas J. Manion Frcp(C) (Age 62)
    M.D., CEO, President & Director
    Comp: $572.16k
  • Dr. Joseph Monahan Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $600.02k
  • Dr. Gail Cawkwell M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $371.17k
  • Mr. Kevin Balthaser (Age 36)
    Chief Financial Officer
  • Mr. Robert A. Doody Jr.
    Senior Vice President of Investor Relations
  • Mr. Matthew Rothman J.D.
    General Counsel & Corporate Secretary
  • Ms. Jill Conwell
    Chief People Officer
  • Mr. Gary A. DeCrescenzo
    Senior Vice President of Pharmaceutical Research & Development
  • Dr. Jon Jacobsen Ph.D.
    Senior Vice President of Chemistry














ACRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price target for 2024?

8 equities research analysts have issued 12-month price objectives for Aclaris Therapeutics' stock. Their ACRS share price targets range from $9.00 to $38.00. On average, they expect the company's stock price to reach $23.17 in the next twelve months. This suggests a possible upside of 2,548.5% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of 2023. Since then, ACRS stock has decreased by 94.4% and is now trading at $0.8747.
View the best growth stocks for 2023 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,390,000 shares, an increase of 12.3% from the October 31st total of 6,580,000 shares. Based on an average daily trading volume, of 3,720,000 shares, the days-to-cover ratio is currently 2.0 days.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its earnings results on Monday, November, 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.07. The biotechnology company earned $9.30 million during the quarter, compared to analysts' expectations of $1.57 million. Aclaris Therapeutics had a negative net margin of 534.83% and a negative trailing twelve-month return on equity of 64.53%. The business's revenue for the quarter was down 51.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share.

What ETFs hold Aclaris Therapeutics' stock?
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Blackstone Inc. (1.78%), Assenagon Asset Management S.A. (0.97%), FMR LLC (0.93%), Charles Schwab Investment Management Inc. (0.65%), Lord Abbett & CO. LLC (0.64%) and HighTower Advisors LLC (0.52%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACRS) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -